Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04439695 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
A Phase 1 study, sponsored by KBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT04439695 is a Phase 1 study that has completed, run by KBio. The registered enrollment target is 120 participants.
The verdict
NCT04439695, a Phase 1 study, has completed, sponsored by KBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is an observer-blinded, randomized, placebo-controlled, parallel group study to evaluate safety and immunogenicity of TAP-V001 quadrivalent influenza vaccine in healthy adult subjects.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Low dose
- BIOLOGICAL Intermediate dose
- BIOLOGICAL High dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-06-25 |
| Est. Completion | 2021-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04439695
The ClinicalTrials.gov registry entry for NCT04439695 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is KBio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04439695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04439695 about?
NCT04439695 is a clinical study titled "Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults". This is an observer-blinded, randomized, placebo-controlled, parallel group study to evaluate safety and immunogenicity of TAP-V001 quadrivalent influenza vaccine in healthy adult subjects.
What is the current status of trial NCT04439695?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2020-06-25. Estimated completion is 2021-07-28.
What interventions are being tested in trial NCT04439695?
The interventions under investigation include: Placebo (BIOLOGICAL), Low dose (BIOLOGICAL), Intermediate dose (BIOLOGICAL), High dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT04439695?
This trial is sponsored by KBio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.